Coronavirus health scams are rampant, with businesses taking advantage of peoples fears to sell all sorts of unproven products for the prevention and treatment of COVID-19. Some of these snake oil cures are innocuous, such as elderberry juice, but others can be harmful, such as colloidal silver.
Among the products with considerable potential for harm are unproven stem cell therapies. Unfortunately, the emergence of this particular line of sham COVID-19 treatments isnt all that surprising. For more than a decade, businesses have been aggressively pitching unsubstantiated and unlicensed stem cell products to vulnerable and often desperate individuals with illnesses or injuries for which no known treatment exists, such as Alzheimers disease, amyotrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD) and spinal cord injuries. The results have sometimes been deadly.
There are some medical conditions for which stem cell therapies have been shown to be safe and effective, but they are few in number mostly cancer and several blood and immune disorders.
Leigh Turner, a bioethicist at the University of Minnesota, has been investigating the direct-to-consumer marketing of spurious stem cell therapies and related exosome products in the United States for nearly a decade. In an article published recently in the journal Cell Stem Cell, Leigh describes the latest twist in this cynical saga: how some stem cell businesses are seizing the [COVID-19] pandemic as an opportunity to profit from hope and desperation.
MinnPost spoke with Turner late last week about what he found when researching that paper. The following is an edited transcript of the interview.
MinnPost: Companies seem to be using the same kind of marketing strategies to sell unproven stem cell therapies for COVID-19 as they have for other medical conditions.
Leigh Turner: Yes. These are opportunistic businesses. They look for marketplace opportunities, ways to generate e-revenue streams. And the COVID-19 pandemic is another business opportunity. Its not like theyve pivoted away from what they did in the past. If they were marketing stem cell treatments for Parkinsons disease, or ALS or spinal injuries, they havent stopped doing that. Theyve just added that theyve now got a stem cell treatment or an exosome therapy to treat or prevent COVID-19.
MP: They seem to be marketing their products primary as immune system boosters.
MP: At least one company is telling people that they should bank their stem cells to use as a treament if they get infected with the coronavirus.
LT: There are several business models at play right now. One is, come on in and get your stem cell immune booster to reduce your chances of getting COVID-19. They may also claim it will reduce your symptoms should you get it. Another marketing pitch is a bit more cautious. It says that if you come in now when youre in good health, they will bank your cells. Youll pay for the initial extraction of cells and also monthly or yearly for banking. The company then claims that should you fall ill with COVID-19 down the road, youll have those healthy cells available for you to use. Of course, they dont offer a lot of detail about how the cells would actually help you. You just supposed to take it for granted that they will.
MP: Theres no evidence of that.
LT: No. Its all just pseudoscience. But there is a meaningful hypothesis behind it. Thats how these businesses operate by fusing science with pseudoscience, credible research with junk claims.
MP: What is that hypothesis?
LT: There are companies and academic institutions right now that are interested in testing stem cell products, but not as immune boosters, not to prevent COVID-19 and not to eliminate the virus if someone gets infected. The studies right now are focusing on a very particular population of people with COVID-19 those who are typically in ICUs, suffering from acute respiratory distress syndrome. The hypothesis is that if certain types of stem cell products are administered to those people, we may be able to reduce inflammation in the lungs and help shorten the illness. But its a hypothesis.
MP: A good one?
LT: Its not an outrageous hypothesis. If you look at the existing literature, there have been studies done in the past that used stem cells for lung and respiratory disease. So far, those studies suggest that if you use clinical-grade stem cells and if you do it in a very rigorous way the safety profile is pretty good. But none of those studies has established extensive evidence of efficacy yet. Ideally, what you want is carefully designed, carefully conducted clinical trials testing that hypothesis and generating that evidence. These businesses the ones marketing stem cell therapies directly to individuals are not part of that scientific world.
MP: How do those businesses pull their customers in? How do they find them?
LT: They are typically big on social media. Im talking generally here, but they have Twitter accounts. They have YouTube channels. They have a Facebook page. Theyre not just putting up a website and hoping that somebody walks in the door. They hire social media marketing companies. They use marketing firms. They have pretty sophisticated marketing strategies that are tailored to particular demographics. It may be that they are targeting an elderly population, for example, because if youre interested in reaching people with COPD, youre not going to be trying to find 18-year-olds. Some businesses here in Minneapolis and elsewhere will have what they describe as educational seminars, which are basically infomercials. They are marketing events. They will try to get people to come to a convention center, a hotel [conference] room or a restaurant. Everything is free, but what theyll do is use hard-sell sales tactics to get people to commit, to write a check. Often theyll tell people that if they sign on today, theyll knock $2,000 or so off the price. But, of course, theyre not holding these events right now. They cant have these public gatherings.
MP: So, how are they selling people these products now, during the pandemic?
LT: More of it is happening online. One company, for example, uses a graduated pricing model. If its one person, its one price point. If its you and a family member, you both get a break on the procedure. And if its you and two additional family members, the price goes down even more. They use these things to try to get people to come in the door. One company in California has adapted to the pandemic in a different way. They have a do-it-yourself model. You dont have to even come into the clinic. You can buy their kit, and they ship it to your home. You then do the procedure at your dining room table.
MP: These stem cell products and treatments are quite expensive.
LT: Yes, some of the businesses Ive look at charge tens of thousands of dollars, although thats not necessarily for treating COVID-19. For COVID-19, it appears to be in the thousands-of-dollars category. In some cases, we dont know. The businesses can be pretty cagey. In some cases, they try to size up the customer and figure out how much they can extract from that person.
MP: Government agencies are cracking down on some of these stem cell businesses.
LT: The FDA (Food and Drug Administration), FTC (Federal Trade Commission) and Department of Justice have said that theyre going to be aggressive with dealing with these scams. And they have. Some businesses have already received letters from the regulators. That may be having a deterrent effect during the pandemic. Some businesses may want to jump in, but are afraid to do so. They may be waiting to see what happens before they take the chance.
MP: But the regulatory agencies are obviously not finding all of the businesses marketing unproven COVID-19 therapies.
LT: There is a lot of marketing fraud. And sometimes its quite challenging to figure out whats going on. Some of the clinics that I looked at didnt say, Were offering an immune booster for COVID-19. It was more just chatter. Clinics would put up a seven-minute video from one of their doctors about COVID-19 and emerging stem-cell research coming out of China, saying it was really encouraging. Then they would say, If you have any questions about stem cells and COVID-19, give us a call. So, whats the takeaway when a business does that? Does that mean they are selling stem cell treatments for COVID-19? Or are they just trying to get people to call? Its hard to know whats happening. If I had to guess, I say its a workaround. The businesses dont want to put it on their website, because thats too easy for someone from the FTC or the FDA to find. If they just put up a video, they can say theyre not marketing anything, that it was just meant to be educational.
MP: These businesses seem to rely on anecdotal cases or really small studies from China to support their claims.
LT: They use China in a couple of different ways. There was a case report, for example, that was published as a preprint. It wasnt published by a journal. It hasnt gone through peer review. It was just a preprint that someone put online. Its the case of a single individual with COVID-19 who received stem cells. Thats been written up in a very hyperbolic way, when really, its just a case report. Its one person. Some people get COVID-19 and recover anyway. You cant draw any conclusions from it about stem cells being efficacious, but its been written up that way. There was another study, very preliminary research, in which mesenchymal stem cells were administered to seven individuals with COVID-19 with various degrees of severity. A placebo was given to three individuals. The article doesnt provide the source of the stem cells. Nor does it provide much insight about the individuals who were given placebos, although they appear to be about 10 years older than [those receiving the stem cells]. It raises some interesting questions. It provides a basis for further research. But, unfortunately, some of the news media reports have been hyperbolic. Stem cell businesses use both these papers when marketing directly to consumers. They refer to these studies, and they also attach themselves to the bubbly media coverage.
MP: Consumers need to know that these products can be dangerous.
LT: Yes. The danger comes in several forms. Part of it is that these are financial scams lifting money off people who are worried and anxious. But, also, giving someone a product that hasnt been carefully tested in well-designed clinical trials raises a lot of concerns. Some businesses have released contaminated stem cell products into the marketplace. People end up getting infections and having to be hospitalized. It can be a very serious thing. Theres also the possibility that the wrong type of cell goes to the wrong part of the body and causes harm. When a company claims, for example, that a stem cell product will regenerate lung tissue and be an immune booster, one thing I would worry about is pulmonary embolisms. If someone is being given something that hasnt been thoroughly tested, its hard to know what would go wrong, but its easy to know something could go wrong.
FMI: Youll find the article on Cell Stem Cells website.
- Impacts of the COVID-19-Mesenchymal Stem Cells Market Size Current and Future Industry Trends, 2020-2028 - 3rd Watch News - July 4th, 2020
- IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News - July 4th, 2020
- Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors - StreetInsider.com - July 4th, 2020
- Biology of Mesenchymal Stem Cells | Bentham Science - July 1st, 2020
- Mesenchymal Stem Cells and Skeletal Regeneration ... - July 1st, 2020
- Amniotic Membranes Market is Projected to Expand at a CAGR of ~10% From 2019 to 2027 - Science Examiner - July 1st, 2020
- Mesenchymal Stem Cells Market 2020 Projections, Growth Opportunities, Trends, Companies Strategies and Forecast 2024 | Lonza, Thermo Fisher,... - July 1st, 2020
- Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute... - June 30th, 2020
- Amniotic Membrane Market by Product, Application and Forecast to 2027 TMR - 3rd Watch News - June 30th, 2020
- Human Primary Cells Market Global ? How the Market has witnessed Substantial Growth in recent years? - 3rd Watch News - June 30th, 2020
- Exosome Therapeutic Market Size, 2020-New Technological Change Helping Market, Application, Driver, - PharmiWeb.com - June 30th, 2020
- Research on Human Mesenchymal Stem Cells (hMSC) Market (impact of COVID-19) with Top Players: PromoCell, ThermoFisher, KURABO, Merck, and - 3rd Watch... - June 23rd, 2020
- Stem Cell Manufacturing Market 2020 Global Size, Share, Progress Insight, Share, Trends, Industry Key Players-Merck Group, Becton, Dickinson And... - June 23rd, 2020
- Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle - June 23rd, 2020
- Exosome Therapeutic Market 2020 Opportunity Ahead of Earnings with evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics... - June 23rd, 2020
- Mesenchymal Stem Cells Market to Witness Robust Expansion throughout the Forecast 2020 - Owned - June 19th, 2020
- Worldwide Stem Cell Therapy Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunities - PRNewswire - June 19th, 2020
- Human Primary Cells Market Regional Analysis, key Drivers and Restraints, by Product, Top Players and Forecast Analysis 2020-2026 - Bulletin Line - June 19th, 2020
- Impressive Trends and Future Scope of Mesenchymal Stem Cells Market - 3rd Watch News - June 14th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 14th, 2020
- MSC Therapy for Acute Respiratory Distress Syndrome; It's Time to Accelerate Clinical Trials for COVID-19 Patients in Need - P&T Community - June 8th, 2020
- COVID-19 Therapeutics: The Leading Contenders - Seeking Alpha - June 6th, 2020
- Global Mesenchymal Stem Cells Market Expected to Witness the Highest Growth during 2020-2026 - Jewish Life News - June 6th, 2020
- AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19 - Pharmaceutical... - June 3rd, 2020
- AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other... - June 3rd, 2020
- Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News - June 3rd, 2020
- Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News - June 3rd, 2020
- Stem Cell Treatments Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - 3rd Watch News - June 3rd, 2020
- MSC Therapy for Acute Respiratory Distress Syndrome; It's Time to Accelerate Clinical Trials for COVID-19 Patients in Need - PRNewswire - June 3rd, 2020
- Global Stem Cell Characterization Kits Market : Analysis and In-depth Study on Market Size Trends, Emerging Growth Factors and Forecasts to 2029 - The... - June 3rd, 2020
- Mesoblast (ASX:MSB) reveals promising trial results for lung disease treatment - The Market Herald - June 3rd, 2020
- Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells | DNA RNA and Cells | News... - June 2nd, 2020
- Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty - June 2nd, 2020
- Photoaged Skin Therapy with Adipose-Derived Stem Cells - MedicalResearch.com - June 2nd, 2020
- Intravenously Delivered Mesenchymal Stem Cells Prevent Microvascular Obstruction Formation After Myocardial Ischemia/Reperfusion Injury - DocWire News - June 2nd, 2020
- COVID-19: Responding to the business impacts of Mesenchymal Stem Cells Market Trends Analysis, Top Manufacturers, Shares, Growth Opportunities,... - June 2nd, 2020
- Mesenchymal Stem Cells Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News - June 2nd, 2020
- Global Human Primary Cells Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Bandera County Courier - June 2nd, 2020
- Could Cell Therapy Target the Symptoms of Severe... - Labiotech.eu - May 25th, 2020
- The Week Ahead In Biotech: ASCO Presentations In The Spotlight - Yahoo Finance - May 25th, 2020
- In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with... - May 23rd, 2020
- We now have a special power to kill the virus - Bangalore Mirror - May 23rd, 2020
- Cells for Cells and Austrianova announce publication on novel method to produce stem cell exosomes - BioSpace - May 23rd, 2020
- Clinical Trial Shows Topical Stem Cell Treatment Leads to Hair Regrowth in Common Type of Baldness - Technology Networks - May 19th, 2020
- NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Business... - May 19th, 2020
- Can stem cell therapy help - Greater Kashmir - May 19th, 2020
- Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths - Business Wire - May 19th, 2020
- Cell Freezing Media for Cell Therapy Market to Exhibit Impressive Growth of CAG - News by aeresearch - May 19th, 2020
- Latest Study explores the Microencapsulated Omega3 Powder Market Witness Highest Growth in near future - AlgosOnline - May 16th, 2020
- Coronavirus Diaries: A Covid scientist on the hunt for a cure, and a GP on what doctors need to learn - Financial Times - May 16th, 2020
- Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Monthly Prescribing Reference - May 16th, 2020
- Umbilical cord stem cells have the potential to treat COVID-19 - Open Access Government - May 14th, 2020
- Global Mesenchymal Stem Cells Market 2020 with (Covid-19) Impact Research by Top Manufacturers, Industry Growth, Regional Analysis and Forecast by... - May 14th, 2020
- Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual... - May 14th, 2020
- The Latest Technological Innovations in Orthopedic Surgery 2020 Technology - IMC Grupo - May 14th, 2020
- AMC to use stem cell therapy in treating graft-versus-host disease - Korea Biomedical Review - May 7th, 2020
- 5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy - Seeking Alpha - May 7th, 2020
- Characterization and Immunomodulation of Canine Amniotic Membrane Stem | SCCAA - Dove Medical Press - May 7th, 2020
- FDA Approves AstraZeneca's Farxiga for Heart Failure in Adults with Reduced Ejection Fraction - BioSpace - May 7th, 2020
- DIABETES RESEARCH INSTITUTE FOUNDATION RECEIVES $3 MILLION GIFT FROM NORTH AMERICA'S BUILDING TRADES UNIONS TO FUND CELL THERAPY FOR COVID-19 -... - May 7th, 2020
- Pass the MUST-ARDS: Athersys starts pivotal study for stem cells to treat COVID-19-induced ARDS - BioWorld Online - May 7th, 2020
- Mesenchymal Stem Cell - an overview | ScienceDirect Topics - May 5th, 2020
- Frontiers | Senescence in Mesenchymal Stem Cells ... - May 5th, 2020
- Investigational new drug may be beneficial in treating severe COVID-19 - BioNews - May 5th, 2020
- BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure -... - May 5th, 2020
- Mesenchymal Stem Cells | Properties, Process, Functions ... - May 5th, 2020
- Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19 - MPR - Monthly Prescribing Reference - May 5th, 2020
- Cell Freezing Media for Cell Therapy Market Expected to Witness the Highest Grow - News.MarketSizeForecasters.com - May 5th, 2020
- Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification - Science Advances - April 30th, 2020
- Biopharmas work to wallop COVID-19 respiratory effects, keeping patients off ventilators - BioWorld Online - April 30th, 2020
- EMA warns against unproven therapies - English - Agenzia ANSA - April 30th, 2020
- US FDA Allows Trial to Proceed for Retrotopes RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP) - Yahoo Finance - April 28th, 2020
- Stem cell therapy shows 83% survival of Coronavirus patients on ventilators - International Business Times, Singapore Edition - April 26th, 2020
- Researcher says stem cell activation could lie at root of health effects of many natural products - NutraIngredients-usa.com - April 26th, 2020
- Mesenchymal Stem Cells: The 'Other' Bone Marrow Stem Cells - April 24th, 2020
- The Dual Nature of Mesenchymal Stem Cells (MSCs): Yin and ... - April 24th, 2020
- Mesenchymal - Stemcell Technologies - April 24th, 2020
- Stem Cells Market Outlook with a Focus on Clinical Therapies 2020-2030: Types of Stem Cells, Route of Administration, Therapeutic Areas, End-users,... - April 24th, 2020
- Mesenchymal stem cells as a potential treatment for ... - April 24th, 2020
- Researchers turn to stem cells in COVID-19 battle How does the treatment work and does it pose any risk? - Times Now - April 24th, 2020